IL1B and acute myeloid leukemia: Short-term treatments with IL-1RN or with the human IL-1β mAb canakinumab were efficient in reducing the expansion of human leukemic cells, i.e. myeloid cells, to similar extents in the PB of NSG-SGM3 mice transplanted with CD34+ progenitors isolated from the BM of AML patient samples (Fig. 1j; Supplementary Fig. S1I).